Eli Lilly and Roche Diagnostics have joined an industry consortium that will help launch a new research institute in Indiana that plans to hire a staff of about 100 investigators to pursue new treatments for a slate of metabolic diseases.
Ex-BlackBerry chief and co-founder Mike Lazaridis has given life to a $97 million fund to advance quantum technology, which has major implications for computing, medicine and other fields.
After failing in its bid for Illumina last year, the Swiss drugmaker has reportedly joined the bidding for Life Technologies, another diagnostics-focused company that sells lab equipment and supplies, including DNA-sequencing machines.
The FDA granted its blessing to Lymphoseek, the first new lymph-node mapping drug in more than 30 years.
Ignyta will work with Leiden University Medical Center on new biomarker research involving patients with early synovitis and rheumatoid arthritis.
The International Diagnostics Centre (IDC) is launched at the U.K.'s London School of Hygiene & Tropical Medicine.
Foundation Medicine, a genetics startup that makes cancer diagnostics tests, has managed to pique the interest of Bill Gates, among other benefactors. That has helped reel in $13.5 million in financing for the small biotech, expanding the total amount of a Series B financing round to $56 million.
Johnson & Johnson CEO Alex Gorsky issued a tidbit sure to whet analysts' appetite for sales, spin-offs and company break-ups of any kind. J&J may sell off its Ortho Clinical Diagnostics unit, provided the price is right.
While Eli Lilly struggles with development of its therapy for treating Alzheimer's disease, its diagnostic imaging agent for helping diagnose, or rule out, the condition has gotten another approval, this time in Europe.
Diagnostics are not always perceived as being as exciting or glamorous as therapeutics, but this is a field that is growing and changing just as fast. The one thing that all of these have in common is innovative and exciting science and design, and the opportunity to make patients' lives better. Read the report >>